Abstract
The COVID‐ 19 pandemic is a global problem for both the management of patients with acute disease and post-cystic complications. Against the background of COVID-19, the development of systemic inflammation is often observed, accompanied by a "cytokine storm", hemostasis disorders and severe vasculitis. New evidence suggests that impaired regulation of lipid metabolism may contribute to the development of these complications. This review summarizes the
latest information on the potential mechanisms associated with dyslipidemia against the background of COVID-19. In particular, it has been suggested that changes in the amount and composition of high-density lipoproteins (HDL) in COVID-19 may significantly weaken the anti-inflammatory and antioxidant effects of HDL and contribute to inflammation in the lungs. In addition, it has been hypothesized that lipoproteins with oxidized phospholipids and fatty acids can lead to viral organ damage due to hyperactivation of scavenger receptors ("scavenger receptors") of innate immunity.